Ultragenyx Pharmaceutical Inc. (RARE) shareholders
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vanguard Portfolio Management | 8,481,266 | 8.60% | 13G (passive) amendment | Sep 30, 2026 |
| BlackRock, Inc. | 8,141,384 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| RTW Investments, LP Joint filing with Roderick Wong (7.90%) | 7,796,895 | 7.90% | 13G (passive) | Jun 30, 2026 |
| State Street Corporation Joint filing with Ssga Funds Management, Inc. (5.40%) | 7,538,078 | 7.60% | 13G (passive) | Sep 30, 2026 |
| AQR Capital Management Holdings, LLC Joint filing with AQR Capital Management, LLC (6.66%) | 6,560,809 | 6.66% | 13G (passive) | Jun 30, 2026 |
| Madison Avenue Partners, LP Joint filing with Madison Avenue International LP (6.40%), EMAI Management, LLC (6.40%) and 3 more | 6,307,798 | 6.40% | 13G (passive) | Oct 13, 2026 |
| Vanguard Capital Management | 5,058,419 | 5.13% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RARE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,654,276 | 10.81% | $355.75M | +3,354,678 | 0.01% |
| Rtw Investments, LP | 7,796,895 | 7.91% | $260.34M | +4,148,100 | 2.22% |
| Vanguard Portfolio Management LLC | 6,790,135 | 6.89% | $226.72M | +1,404,143 | 0.01% |
| Aqr Capital Management LLC | 6,560,809 | 6.65% | $214.14M | +1,982,785 | 0.07% |
| State Street Corp | 6,158,766 | 6.25% | $205.64M | +1,137,325 | 0.01% |
| Vanguard Capital Management LLC | 4,296,491 | 4.36% | $143.46M | +106,660 | 0.00% |
| Two Sigma Investments, LP | 3,621,200 | 3.67% | $120.91M | +1,415,380 | 0.09% |
| Sands Capital Management, LLC | 3,158,368 | 3.20% | $105.46M | −56,165 | 0.39% |
| Jacobs Levy Equity Management, Inc | 2,939,719 | 2.98% | $98.16M | +1,508,648 | 0.35% |
| Frontier Capital Management Co LLC | 2,847,936 | 2.89% | $95.09M | +656,754 | 0.89% |
| Geode Capital Management, LLC | 2,578,828 | 2.62% | $86.12M | +729,437 | 0.00% |
| Bellevue Group AG | 1,982,775 | 2.01% | $66.20M | −397,225 | 1.39% |
| D. E. Shaw & Co., Inc. | 1,730,193 | 1.75% | $57.77M | +469,175 | 0.03% |
| Sofinnova Investments, Inc. | 1,717,505 | 1.74% | $57.35M | −1,428,383 | 2.96% |
| Adage Capital Partners Gp, L.L.C. | 1,580,000 | 1.60% | $52.76M | +1,100,000 | 0.07% |
| GW&K Investment Management, LLC | 1,481,178 | 1.50% | $49.46M | −134,248 | 0.39% |
| Mpm Bioimpact LLC | 1,418,215 | 1.44% | $47.35M | New | 2.89% |
| Price T Rowe Associates Inc /Md/ | 1,356,501 | 1.38% | $45.30M | +552,392 | 0.00% |
| Morgan Stanley | 1,324,805 | 1.34% | $44.24M | −175,723 | 0.00% |
| Wellington Management Group Llp | 1,250,464 | 1.27% | $41.75M | −1,390,348 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 310 | 107M | 100.0% | 59 / 116 | 98 / 44 | 28M | 19M |
| Q1 2026 | 298 | 98M | 99.6% | 63 / 125 | 84 / 49 | 42M | 27M |
| Q4 2025 | 288 | 94M | 95.3% | 57 / 111 | 91 / 65 | 19M | 23M |
| Q3 2025 | 303 | 100M | 100.0% | 53 / 131 | 91 / 57 | 27M | 21M |
| Q2 2025 | 310 | 94M | 95.5% | 54 / 117 | 108 / 43 | 14M | 10M |
| Q1 2025 | 300 | 90M | 91.2% | 34 / 126 | 105 / 44 | 10M | 7M |
| Q4 2024 | 313 | 88M | 88.8% | 55 / 111 | 109 / 42 | 10M | 10M |
| Q3 2024 | 302 | 87M | 88.4% | 59 / 110 | 93 / 29 | 15M | 11M |
| Q2 2024 | 275 | 89M | 90.1% | 47 / 117 | 80 / 40 | 17M | 9M |
| Q1 2024 | 270 | 81M | 82.3% | 53 / 100 | 76 / 20 | 7M | 8M |
| Q4 2023 | 237 | 82M | 82.8% | 44 / 95 | 74 / 23 | 17M | 6M |
| Q3 2023 | 220 | 71M | 72.3% | 11 / 105 | 73 / 33 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
265 funds held RARE in Q2 2026, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RARE | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,666,868 | 3.72% | $122.44M | 1.14% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,986,621 | 3.03% | $99.72M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,501,996 | 2.54% | $83.54M | 0.10% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,144,802 | 2.18% | $71.61M | 0.04% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,238,640 | 1.26% | $41.36M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,127,711 | 1.14% | $37.65M | 0.04% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 1,072,214 | 1.09% | $35.80M | 0.29% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,055,493 | 1.07% | $26.29M | 0.08% | Jul 31, 2026 |
| AQR Long-Short Equity Fund | 914,718 | 0.93% | $30.54M | 0.39% | Jun 30, 2026 |
| Vanguard Explorer Fund | 821,986 | 0.83% | $20.48M | 0.09% | Jul 31, 2026 |
| iShares Biotechnology ETF | 635,346 | 0.64% | $21.21M | 0.23% | Jun 30, 2026 |
| Touchstone Funds Group Trust-Touchstone Sands Capital Select Growth Fund | 611,950 | 0.62% | $20.43M | 0.92% | Jun 30, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 527,813 | 0.54% | $12.64M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 500,243 | 0.51% | $11.98M | 0.03% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 496,620 | 0.50% | $16.58M | 0.11% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Emil D. Kakkis | President & CEO, Director | 2,694,724 | 2.73% | Apr 20, 2026 |
| Howard Horn | Chief Financial Officer | 89,229 | 0.09% | Oct 19, 2026 |
| Theodore Alan Huizenga | SVP, Chief Accounting Officer | 67,863 | 0.07% | Sep 15, 2026 |
| Karah Herdman Parschauer | EVP and Chief Legal Officer | 92,562 | 0.09% | Aug 4, 2026 |
| Eric Crombez | EVP and Chief Medical Officer | 111,189 | 0.11% | May 6, 2026 |
| John Richard Pinion | See Remarks | 133,142 | 0.14% | Apr 20, 2026 |
| Dennis Karl Huang | See Remarks | 147,845 | 0.15% | Apr 20, 2026 |
| Erik Harris | EVP & Chief Commercial Officer | 118,410 | 0.12% | Apr 20, 2026 |
| Thomas Richard Kassberg | CBO & EVP | 265,238 | 0.27% | Mar 4, 2025 |
| Corazon (Corsee) D. Sanders | Director | 21,095 | 0.02% | Jun 15, 2026 |
| Daniel G. Welch | Director | 40,441 | 0.04% | May 18, 2026 |
| Michael Narachi | Director | 40,441 | 0.04% | May 18, 2026 |
| Deborah Dunsire | Director | 38,566 | 0.04% | May 18, 2026 |
| Amrit Ray | Director | 31,116 | 0.03% | May 18, 2026 |
| Shehnaaz Suliman | Director | 27,951 | 0.03% | May 18, 2026 |
| Matthew K. Fust | Director | 33,696 | 0.03% | May 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Howard Horn Chief Financial Officer | Oct 15, 2026 | Sale | −7,066 | $15.27 | $107.90K | 89,229 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −1,283 | $13.57 | $17.41K | 67,863 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Sep 3, 2026 | Sale | −161 | $13.99 | $2.25K | 69,146 |
| Howard Horn Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −4,696 | $24.92 | $117.02K | 96,295 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −1,900 | $24.92 | $47.35K | 92,562 |
| Howard Horn Chief Financial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −4,698 | $33.13 | $155.64K | 100,991 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −1,899 | $24.62 | $46.75K | 94,462 |
| Corazon (Corsee) D. Sanders Director | Jun 15, 2026 | Sale | −2,000 | $25.05 | $50.10K | 21,095 |
| Howard Horn Chief Financial Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −4,653 | $23.77 | $110.60K | 105,689 |
| Shehnaaz Suliman Director | May 18, 2026 | Sale(10b5-1 plan) | −5,740 | $25.12 | $144.19K | 27,951 |
| Shehnaaz Suliman Director | May 14, 2026 | Award | +7,751 | – | – | 33,691 |
| Michael Narachi Director | May 14, 2026 | Award | +7,751 | – | – | 40,441 |
| Daniel G. Welch Director | May 14, 2026 | Award | +7,751 | – | – | 40,441 |
| Deborah Dunsire Director | May 14, 2026 | Award | +7,751 | – | – | 38,566 |
| Corazon (Corsee) D. Sanders Director | May 14, 2026 | Award | +7,751 | – | – | 23,095 |
| Amrit Ray Director | May 14, 2026 | Award | +7,751 | – | – | 31,116 |
| Matthew K. Fust Director | May 14, 2026 | Award | +7,751 | – | – | 33,696 |
| Eric Crombez EVP and Chief Medical Officer | May 5, 2026 | Sale | −344 | $24.96 | $8.59K | 111,189 |
| Howard Horn Chief Financial Officer | May 1, 2026 | Sale(10b5-1 plan) | −4,683 | $24.90 | $116.61K | 110,342 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Apr 22, 2026 | Award | +20,241 | – | – | 68,911 |
| John Richard Pinion See Remarks | Apr 16, 2026 | Award | +23,116 | – | – | 133,142 |
| Dennis Karl Huang See Remarks | Apr 16, 2026 | Award | +23,116 | – | – | 147,845 |
| Eric Crombez EVP and Chief Medical Officer | Apr 16, 2026 | Award | +34,674 | – | – | 110,975 |
| Howard Horn Chief Financial Officer | Apr 16, 2026 | Award | +34,674 | – | – | 115,025 |
| Emil D. Kakkis President & CEO, Director | Apr 16, 2026 | Award | +76,745 | – | – | 735,739 |
| Erik Harris EVP & Chief Commercial Officer | Apr 16, 2026 | Award | +28,895 | – | – | 118,410 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Apr 16, 2026 | Award | +28,895 | – | – | 95,715 |
| Howard Horn Chief Financial Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −4,683 | $20.97 | $98.20K | 80,351 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Mar 10, 2026 | Sale | −3,508 | $22.67 | $79.53K | 66,820 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Mar 6, 2026 | Sale | −6,018 | $21.40 | $128.79K | 70,328 |
| Howard Horn Chief Financial Officer | Mar 3, 2026 | Sale(10b5-1 plan) | −1,635 | $22.40 | $36.62K | 85,034 |
| Howard Horn Chief Financial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −3,119 | $22.54 | $70.30K | 86,669 |
| Howard Horn Chief Financial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −5,290 | $22.80 | $120.61K | 89,788 |
| Emil D. Kakkis President & CEO, Director | Mar 2, 2026 | Sale | −54,404 | $22.80 | $1.24M | 658,994 |
| Dennis Karl Huang See Remarks | Mar 2, 2026 | Tax withholding | −999 | $23.39 | $23.37K | 124,729 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Mar 2, 2026 | Tax withholding | −148 | $23.39 | $3.46K | 50,302 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Mar 2, 2026 | Sale | −1,632 | $22.80 | $37.21K | 48,670 |
| Erik Harris EVP & Chief Commercial Officer | Mar 2, 2026 | Sale | −10,539 | $22.80 | $240.29K | 89,515 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Mar 2, 2026 | Sale | −8,135 | $22.80 | $185.48K | 76,346 |
| Eric Crombez EVP and Chief Medical Officer | Mar 2, 2026 | Sale | −7,029 | $22.80 | $160.26K | 76,301 |
| John Richard Pinion See Remarks | Mar 2, 2026 | Sale | −10,029 | $22.80 | $228.66K | 110,026 |
| Howard Horn Chief Financial Officer | Mar 1, 2026 | Award | +6,143 | – | – | 95,078 |
| Emil D. Kakkis President & CEO, Director | Mar 1, 2026 | Award | +71,177 | – | – | 712,908 |
| Dennis Karl Huang See Remarks | Mar 1, 2026 | Award | +11,137 | – | – | 125,728 |
| Erik Harris EVP & Chief Commercial Officer | Mar 1, 2026 | Award | +11,643 | – | – | 99,498 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Mar 1, 2026 | Award | +11,137 | – | – | 84,408 |
| Eric Crombez EVP and Chief Medical Officer | Mar 1, 2026 | Award | +11,643 | – | – | 83,173 |
| John Richard Pinion See Remarks | Mar 1, 2026 | Award | +11,137 | – | – | 119,565 |
| Howard Horn Chief Financial Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −3,061 | $23.56 | $72.12K | 88,935 |
| Howard Horn Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −3,150 | $22.84 | $71.95K | 91,996 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Dec 29, 2025 | Sale | −85 | $34.38 | $2.92K | 50,450 |
| Howard Horn Chief Financial Officer | Dec 10, 2025 | Sale(10b5-1 plan) | −3,081 | $36.38 | $112.09K | 95,146 |
| Howard Horn Chief Financial Officer | Oct 13, 2025 | Sale | −7,942 | $31.51 | $250.25K | 98,227 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Sep 18, 2025 | Sale | −64 | $29.17 | $1.87K | 50,242 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Sep 12, 2025 | Sale | −2,450 | $31.17 | $76.37K | 73,271 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Sep 5, 2025 | Sale | −84 | $31.39 | $2.64K | 50,306 |
| Corazon (Corsee) D. Sanders Director | Jun 20, 2025 | Sale(10b5-1 plan) | −2,405 | $37.39 | $89.92K | 15,344 |
| Matthew K. Fust Director | May 15, 2025 | Award | +5,740 | – | – | 25,945 |
| Shehnaaz Suliman Director | May 15, 2025 | Award | +5,740 | – | – | 25,940 |
| Corazon (Corsee) D. Sanders Director | May 15, 2025 | Award | +5,740 | – | – | 17,749 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ultragenyx Pharmaceutical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 159,197 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Theodore Alan Huizenga Officer | Sep 15, 2026 | 1,283 | $17.46K | Sep 15, 2026 | Performance Stock Units |
| Howard Horn Officer | Aug 3, 2026 | 4,696 | $117.02K | Aug 3, 2026 | Restricted Stock and Performance Shares |
| Howard Horn Officer | Jul 1, 2026 | 4,698 | $155.64K | Jul 1, 2026 | Restricted Stock |
| Karah Herdman Parschauer Officer | Jun 15, 2026 | 3,799 | $92.51K | Jun 15, 2026 | Performance Stock Units |
| Corazon (Corsee) D. Sanders Director | Jun 15, 2026 | 2,000 | $50.10K | Jun 15, 2026 | Restricted Stock |
| Howard Horn Officer | Jun 1, 2026 | 4,653 | $110.60K | Jun 1, 2026 | Performance and Restricted Stock |
| Shehnaaz Suliman Director | May 18, 2026 | 5,740 | $144.19K | May 18, 2026 | Restricted Stock |
| Howard Horn Officer | May 1, 2026 | 4,683 | $116.61K | May 1, 2026 | Restricted Stock |
| Howard Horn Officer | Apr 1, 2026 | 4,683 | $98.20K | Apr 1, 2026 | Restricted Stock |
| Karah Herdman Parschauer Officer | Mar 10, 2026 | 3,508 | $79.53K | Mar 10, 2026 | Restricted Stock |
| Karah Herdman Parschauer Officer | Mar 6, 2026 | 6,018 | $128.77K | Mar 6, 2026 | Performance Shares |
| Howard Horn Officer | Mar 3, 2026 | 1,635 | $36.62K | Mar 3, 2026 | Performance Shares |
| Howard Horn Officer | Mar 2, 2026 | 3,119 | $70.30K | Mar 2, 2026 | Restricted Stock |
| Howard Horn Officer | Feb 2, 2026 | 3,061 | $72.12K | Feb 2, 2026 | Restricted Stock |
| Howard Horn Officer | Jan 2, 2026 | 3,150 | $71.95K | Jan 2, 2026 | Restricted Stock |
Congress trades
5 trades in Ultragenyx Pharmaceutical reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | Sep 29, 2026 | $1K–15K | Oct 12, 2026 |
| Gilbert Cisneros CA31 | Bought | Mar 3, 2026 | $1K–15K | Apr 7, 2026 |
| Gilbert Cisneros CA31 | Bought | Feb 18, 2026 | $1K–15K | Mar 9, 2026 |
| Gilbert Cisneros CA31 | Bought | Aug 8, 2025 | $1K–15K | Sep 12, 2025 |
| Gilbert Cisneros CA31 | Bought | Jul 15, 2025 | $1K–15K | Aug 14, 2025 |
See a number that looks wrong?